SEC Company Response from X4 Pharmaceuticals, Inc (XFOR) (CIK 0001501697) (XFOR) — Nov 13, 2017
X4 Pharmaceuticals, Inc (XFOR) (CIK 0001501697)
Date: Nov. 13, 2017 · CIK: 0001501697 · Accession: 0001193125-17-340913
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-221050
Letter
Arsanis, Inc.
890 Winter Street, Suite 230
Waltham, MA 02451
November 13, 2017
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C.
Re: Arsanis, Inc.
Registration Statement on Form S-1
File No. 333-221050
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Arsanis, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-221050), as amended (the “Registration Statement”), so that it may become effective at 4:00 p.m. Eastern time on November 15, 2017, or as soon thereafter as practicable.
[Remainder of Page Intentionally Left Blank]
Very truly yours,
ARSANIS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Arsanis, Inc. 890 Winter Street, Suite 230 Waltham, MA 02451 November 13, 2017 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Arsanis, Inc. Registration Statement on Form S-1 File No. 333-221050 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Arsanis, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-221050), as amended (the “Registration Statement”), so that it may become effective at 4:00 p.m. Eastern time on November 15, 2017, or as soon thereafter as practicable. [Remainder of Page Intentionally Left Blank] Very truly yours, ARSANIS, INC. By: /s/ René Russo Name: René Russo Title: President and Chief Executive Officer Signature Page to Acceleration Request